RenovoRx, Inc.(RNXT)

Biotechnology · Mountain View, CA

$1.38-0.09 (-6.12%)

Delayed quote: Oct 6, 2026, 3:39 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T19:43:10.157Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:43:10.157Z.

Quote observation: 2026-10-06T19:39:47.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 62,172,726
Total debt · period ending 2026-06-30: 259,000
Cash · period ending 2026-06-30: 9,479,000
TTM free cash flow · period ending 2026-06-30: -11,937,000

FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNXT EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

RNXT Competitors' EV/FCF Ratio

RNXT

RenovoRx, Inc.

Current

Market Cap

$62.17M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs RNXT

Market Cap

$61.99M

EV/FCF Ratio

N/A

TTM Avg

1.41x

3Y Avg

1.41x

5Y Avg

1.41x

INCR

InterCure Ltd.

vs RNXT

Market Cap

$63.02M

EV/FCF Ratio

14.40x

TTM Avg

12.61x

3Y Avg

12.61x

5Y Avg

118.68x

KLRS

Kalaris Therapeutics Inc

vs RNXT

Market Cap

$61.12M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs RNXT

Market Cap

$63.47M

EV/FCF Ratio

N/A

TTM Avg

41.03x

3Y Avg

41.03x

5Y Avg

41.03x

ALPS

Alps Group Inc

vs RNXT

Market Cap

$63.56M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs RNXT

Market Cap

$60.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs RNXT

Market Cap

$60.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs RNXT

Market Cap

$58.43M

EV/FCF Ratio

N/A

TTM Avg

108.20x

3Y Avg

108.20x

5Y Avg

108.20x

XLO

Xilio Therapeutics, Inc.

vs RNXT

Market Cap

$58.85M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
RenovoRx, Inc. (RNXT)	$62.17M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$61.99M	N/A	1.41x	1.41x	1.41x
InterCure Ltd. (INCR)vs ›	$63.02M	14.40x	12.61x	12.61x	118.68x
Kalaris Therapeutics Inc (KLRS)vs ›	$61.12M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.47M	N/A	41.03x	41.03x	41.03x
Alps Group Inc (ALPS)vs ›	$63.56M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.04M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$58.43M	N/A	108.20x	108.20x	108.20x
Xilio Therapeutics, Inc. (XLO)vs ›	$58.85M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

RNXT EV/FCF Ratio Metrics

RNXT Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics